Clinical trial
Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma…
NCT00100685 · Abbott, Industry · Terminated
Key facts
| NCT number | NCT00100685 |
|---|---|
| Title | Study of M200 (Volociximab) in Patients With Metastatic Renal Cell Carcinoma (RCC) |
| Official title | Phase 2 Open-Label Study of Volociximab (M200) in Patients With Metastatic Renal Cell Carcinoma |
| Lead sponsor | Abbott, Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Renal Cell Carcinoma, Metastases |
| Intervention type | Drug |
| Interventions | Volociximab (anti-α5β1 integrin monoclonal antibody) |
| Enrollment | 48 |
| Start date | Jan 1, 2005 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jan 5, 2005 |
| Last update posted | Apr 27, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: